Table 2.

Individual Data on Patients Receiving Single-Agent nab-Paclitaxel

Patient #	Age	Sex	Histology	KPS	Chemotherapy For Earlier Stage Disease	Platinum-Refractory	Prior Taxane	Line of Therapy	Started Standard Dose	Dose Reduced	# of Cycles Given	Best Overall Response
1	51	Male	AdenoCA	80	No	No	Yes	4th	No	No	3	PD
2	72	Male	AdenoCA	60	No	No	No	2nd	No	Yes	40	PR
3	75	Female	AdenoCA	70	No	No	No	3rd	No	No	19	SD
4	60	Female	AdenoCA	70	Yes	No	No	3rd	Yes	Yes	11	PR
5	71	Male	Mixeda	70	No	No	No	2nd	Yes	No	2	PD
6	67	Female	AdenoCA	80	No	No	No	3rd	Yes	No	18	SD
7	71	Female	AdenoCA	70	No	No	Yes	4th	No	No	9	SD
8	55	Female	AdenoCA	80	Yes	No	Yes	2nd	Yes	No	3	SD
9	78	Male	SCC	70	No	Yes	No	2nd	No	No	4	SD
10	82	Female	SCC	80	No	No	No	3rd	Yes	N/A	1	SD
11	59	Female	AdenoCA	70	Yes	No	Yes	4th	Yes	N/A	1	PD
12	70	Male	AdenoCA	70	No	No	No	2nd	Yes	No	2	PD
13	48	Male	AdenoCA	70	Yes	No	Yes	2nd	Yes	Yes	2	PD
14	61	Male	AdenoCA	80	Yes	No	Yes	4th	Yes	No	5	SD
15	58	Female	AdenoCA	70	No	No	No	4th	Yes	No	2	PD
16	79	Female	Large Cell	70	Yes	Yes	Yes	2nd	No	Yes	6	PR
17	69	Male	AdenoCA	70	No	No	No	3rd	No	No	6	SD
18	78	Male	AdenoCA	70	No	Yes	No	2nd	Yes	No	2	PD
19	60	Female	AdenoCA	80	No	No	No	4th	No	No	4	SD
20	57	Female	AdenoCA	70	No	No	No	3rd	Yes	No	2	PD
21	66	Female	AdenoCA	80	No	No	No	2nd	No	Yes	9	SD
22	65	Female	AdenoCA	90	No	No	No	3rd	Yes	No	5	SD
23	56	Female	AdenoCA	70	No	No	No	2nd	No	No	3	PD
24	81	Male	AdenoCA	80	No	No	No	2nd	No	No	8	SD
25	69	Male	SCC	70	No	No	No	3rd	No	No	2	PD
26	78	Male	AdenoCA	50	No	No	No	4th	No	Yes	6	SD
27	80	Male	AdenoCA	80	No	No	No	2nd	No	No	2	PD
28	61	Female	AdenoCA	80	No	No	No	2nd	Yes	No	8	PR
29	83	Male	AdenoCA	80	No	Yes	No	3rd	No	No	4	SD
30	69	Male	AdenoCA	60	No	No	No	3rd	No	Yes	3	SD
31	60	Male	AdenoCA	70	No	Yes	No	3rd	Yes	Yes	6	PR

^aMixed = Mixed Adenocarcinoma and Squamous Cell Carcinoma

Abbreviations: AdenoCA = Adenocarcinoma; SCC = Squamous Cell Carcinoma; KPS = Karnofsky Performance Status; PR = Partial Response; SD = Stable Disease; PD = Progressive Disease; N/A = Not Applicable